Sign In
Buy NVZMY
$65.04
-0.650 (-0.99%)
At Close: Jul 31, 2026
Animal Growth Promoter Market 2021: Emerging Growth Trends and Top Key Players Zoetis, Yiduoli, Royal DSM N.V, Novus International, Novozymes, Merck Animal Health
10:27am, Wednesday, 22'nd Dec 2021 OpenPR
Animal Growth Promoter Market 2021 A complete explanation of industrial capacity, ever-increasing demand, sales, and future growth possible is included in the market study and also a CAGR % forecasted from 2021 to 2027. The Animal Growth Promoter market report contains
Novozymes A/S (OTCMKTS:NVZMY) Sees Significant Decline in Short Interest
11:42pm, Saturday, 18'th Dec 2021 Transcript Daily
Novozymes A/S (OTCMKTS:NVZMY) saw a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 5,300 shares, a decrease of 37.6% from the November 15th total of 8,500 shares. Based on an average daily volume of 19,200 shares, the days-to-cover ratio is currently 0.3 days. Novozymes []
Novozymes A/S (OTCMKTS:NVZMY) Share Price Passes Above 50 Day Moving Average of $74.89
02:20pm, Saturday, 18'th Dec 2021 Dakota Financial News
Novozymes A/S (OTCMKTS:NVZMY)s stock price crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $74.89 and traded as high as $80.32. Novozymes A/S shares last traded at $79.95, with a volume of 10,242 shares changing hands. A number of research firms have recently []
Latest Business Market Insights added report on North America Synthetic Biology Market research study by Market Digits offers detailed product outlook and elaborates market review till 2027. The market Study is segmented by key regions that is accelerating the marketization.
Probiotic Powder Market to Witness Notable Growth by 2027 Covid-19 Analysis | Glory Biotech, Novozymes
02:33pm, Wednesday, 15'th Dec 2021 OpenPR
This Probiotic Powder market report is an excellent model for new competitors to use when establishing their business because it significantly assists them in increasing earnings while decreasing overall expenses. It boosts the sales rate of the firm even more.
Biostimulants Market Growth Prospects and Outlook 2021- BASF; Bayer CropScience; Novozymes A/S; Koppert Biological Systems; Verdesian Life Sciences
12:18pm, Wednesday, 15'th Dec 2021 OpenPR
Biostimulants Market 2021 report helps the clients to take business decisions and to understand strategies of major players in the industry. The report also calls for market- driven results deriving feasibility studies for client needs. Market Insights Reports ensures qualified
InvAscent exits Synergia life Sciences with over 11-fold returns after sale to Novozymes | VCCircle
10:31am, Monday, 13'th Dec 2021 VCCircle
Healthcare-focussed private equity (PE) firm InvAscent has exited Synergia Life Sciences Pvt Ltd, with over 11-fold returns after
Novozymes and Saipem enter collaboration agreement to create a more sustainable CO2 capture
07:02am, Monday, 13'th Dec 2021 Intrado Digital Media
The partnership will develop new biotech solutions aimed at carbon capture through enzymes.
CE or NVZMY: Which Is the Better Value Stock Right Now?
01:03pm, Friday, 10'th Dec 2021
CE vs. NVZMY: Which Stock Is the Better Value Option?
Novozymes announces closing of transaction of majority stake in Synergia Life Sciences
07:14am, Friday, 10'th Dec 2021 Intrado Digital Media
Please read the full announcement in PDF
Should You Buy Novozymes (NVZMY) Ahead of Earnings?
10:00am, Friday, 12'th Nov 2021
Novozymes (NVZMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
We need to listen to the youth: Novozymes CEO
01:20pm, Friday, 05'th Nov 2021
Leaders at COP26 need to listen to activists and take on board what they're saying so that we can move forward together, says Novozymes CEO Ester Baiget
ICL vs. NVZMY: Which Stock Should Value Investors Buy Now?
01:00pm, Wednesday, 03'rd Nov 2021
ICL vs. NVZMY: Which Stock Is the Better Value Option?
Novozymes A/S (NVZMF) CEO Ester Baiget on Q3 2021 Results - Earnings Call Transcript
02:29pm, Wednesday, 27'th Oct 2021
Novozymes A/S (NVZMF) CEO Ester Baiget on Q3 2021 Results - Earnings Call Transcript
Novozymes is unlocking growth with the ambition of doubling company revenue by 2030
01:19pm, Monday, 27'th Sep 2021
With the launch of “Unlocking Growth – Powered by Biotech” Novozymes presents its 2025-strategy. It sets out an organic sales growth target of 5+% CAGR for the 5-year period until 2025, coupled
